These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25512144)

  • 1. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.
    Huang SC; Ng KF; Lee SE; Chen KH; Yeh TS; Chen TC
    Gastric Cancer; 2016 Jan; 19(1):176-82. PubMed ID: 25512144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.
    Ahn S; Ahn S; Van Vrancken M; Lee M; Ha SY; Lee H; Min BH; Lee JH; Kim JJ; Choi S; Jung SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim KM
    Oncotarget; 2015 Nov; 6(35):38372-80. PubMed ID: 26460823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.
    Xu C; Liu Y; Ge X; Jiang D; Zhang Y; Ji Y; Hou J; Huang J; Su J; Zeng H; Qin J; Hou Y
    Diagn Pathol; 2017 May; 12(1):41. PubMed ID: 28549444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
    Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
    Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.
    Yang J; Luo H; Li Y; Li J; Cai Z; Su X; Dai D; Du W; Chen T; Chen M
    Cell Biochem Biophys; 2012 Jan; 62(1):221-8. PubMed ID: 21927816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
    Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
    Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
    Fazlollahi L; Remotti HE; Iuga A; Yang HM; Lagana SM; Sepulveda AR
    Arch Pathol Lab Med; 2018 Apr; 142(4):516-522. PubMed ID: 28782986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma.
    Nergiz D; Alikanoğlu AS; Süren D; Gömceli İ; Öztürk B
    Indian J Pathol Microbiol; 2022; 65(2):321-327. PubMed ID: 35435366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
    Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
    Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer.
    Tominaga N; Gotoda T; Hara M; Hale MD; Tsuchiya T; Matsubayashi J; Kono S; Kusano C; Itoi T; Fujimoto K; Moriyasu F; Grabsch HI
    Gastric Cancer; 2016 Apr; 19(2):553-560. PubMed ID: 25987463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.
    Chao WR; Lee MY; Ruan A; Sheng HP; Hsu JD; Han CP; Koo CL
    PLoS One; 2015; 10(11):e0142135. PubMed ID: 26566289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients.
    Han X; Shi Y; Ma L; Lyu Z; Yang H; Yao J; Li J; Li B; Qin Y
    Chin Med J (Engl); 2014; 127(2):246-53. PubMed ID: 24438611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy?
    Selcukbiricik F; Erdamar S; Buyukunal E; Serrdengecti S; Demirelli F
    Asian Pac J Cancer Prev; 2014; 15(24):10607-11. PubMed ID: 25605147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
    Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
    Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
    Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
    Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
    Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
    Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.